Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management

June 7, 2022

IR

2cureX, a IVD Diagnostic company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces that the Chairman of the Board of Directors and and Executive Management have purchased shares in the company.

The following share purchases have been conducted:

Shares purchased Total shareholding
Povl-Andre’ Bendz Chairman of the Board 4,775 194,033
Fernando Andreu CEO 6,754 14,741
Kenneth G. Johansen CFO 4,000 4,000
Ole Thastrup CSO 4,000 4,155,134